TLP (TROVE1) Protein

Migration, Crosslink

📖

TLP (TROVE1) Protein

active

wiki page Created: 2026-04-02T07:19:14 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-tlp-protein

📖 Wiki Page

protein2843 wordssynced 2026-04-02

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">TLP (TROVE1)</th></tr>
<tr><td><strong>Protein Name</strong></td><td>TLP (TROVE Domain Containing 1)</td></tr>
<tr><td><strong>Gene Symbol</strong></td><td>[TROVE1](/genes/trove1) (formerly TROVE1)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q9Y5W2](https://www.uniprot.org/uniprot/Q9Y5W2)</td></tr>
<tr><td><strong>PDB Structures</strong></td><td>6D6W, 6D6V</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~60 kDa</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Nucleus, Cytoplasm, Nucleolus</td></tr>
<tr><td><strong>Protein Family</strong></td><td>TROVE domain family</td></tr>
<tr><td><strong>Aliases</strong></td><td>RO60, SSA2, Sjögren's syndrome antigen 2</td></tr>
</table>
</div>

TLP (TROVE1): RNA Exosome Regulator in ALS-FTD

Overview

TROVE Domain Containing 1 (TLP), formerly known as TROVE1 and also called RO60 or SSA2, is a 60 kDa protein associated with the RNA exosome complex that plays critical roles in RNA processing, turnover, and quality control. TLP is implicated in the pathogenesis of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), linking RNA metabolism defects to neurodegeneration.

...

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">TLP (TROVE1)</th></tr>
<tr><td><strong>Protein Name</strong></td><td>TLP (TROVE Domain Containing 1)</td></tr>
<tr><td><strong>Gene Symbol</strong></td><td>[TROVE1](/genes/trove1) (formerly TROVE1)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q9Y5W2](https://www.uniprot.org/uniprot/Q9Y5W2)</td></tr>
<tr><td><strong>PDB Structures</strong></td><td>6D6W, 6D6V</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~60 kDa</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Nucleus, Cytoplasm, Nucleolus</td></tr>
<tr><td><strong>Protein Family</strong></td><td>TROVE domain family</td></tr>
<tr><td><strong>Aliases</strong></td><td>RO60, SSA2, Sjögren's syndrome antigen 2</td></tr>
</table>
</div>

TLP (TROVE1): RNA Exosome Regulator in ALS-FTD

Overview

TROVE Domain Containing 1 (TLP), formerly known as TROVE1 and also called RO60 or SSA2, is a 60 kDa protein associated with the RNA exosome complex that plays critical roles in RNA processing, turnover, and quality control. TLP is implicated in the pathogenesis of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), linking RNA metabolism defects to neurodegeneration.

TLP was originally identified as an autoantigen in Sjögren's syndrome, where autoantibodies against TLP are found in patient sera. Subsequent research revealed its fundamental role in RNA metabolism through association with the RNA exosome—the main exoribonuclease complex responsible for RNA processing and decay in eukaryotic cells.

Structure and Domains

TLP contains several distinct domains that mediate its functions:

TROVE Domain

The namesake TROVE domain (TROVE domain containing 1) spans residues 1-350 and serves as the primary RNA-binding module. This domain:

Binds various RNA species including small nuclear RNAs (snRNAs), small nucleolar RNAs (snoRNAs), and mRNAs
Mediates protein-protein interactions with RNA exosome components
Is conserved across eukaryotes

Additional Domains

Multiple alpha-helical regions: Form the structural core and mediate protein-protein interactions
Nuclear localization signals (NLS): Direct import into the nucleus
C-terminal region: Participates in complex formation with the RNA exosome

Complex Formation

TLP exists in multiple complex[@gao2022]es:

TLP-RNA exosome complex: Primary functional complex for RNA processing

TLP-YBX1 complex: Alternative complex involved in specific RNA metabolism pathways

TLP-LARP7 complex: Associates with the La-related protein LARP7

Normal Physiological Function

RNA Exosome Association

TLP is a key accessory factor [@chen2020]for the RNA exosome complex:

Facilitates substrate recognition and loading
Targets specific RNA species for processing/degradation
Mediates the recruitment of regulatory proteins

RNA Processing Functions

TLP participates in processing numerous RNA species:

snRNA processing: Critical for small nuclear RNA maturation

snoRNA processing: Required for small nucleolar RNA biogenesis

mRNA quality control: Degrades aberrant mRNAs

Non-coding RNA metabolism: Processes various ncRNAs including Alu elements

Cellular Functions

Beyond RNA metabolism, TLP is involved in:

Stress response: TLP is upregulated under cellular stress conditions

Immune regulation: Regulates interferon-stimulated genes

Cell cycle: TLP expression affects cell proliferation

DNA damage response: Participates in DNA repair pathways

Role in Neurodegeneration

Amyotrophic Lateral Sclerosis (ALS)

TLP was identified as an ALS risk gene in 2019 when mutations in TROVE1 were found to cause familial ALS and FTD in multiple families:[@ikeda2019]

Disease-causing mutations: Missense mutations in the TROVE domain impair RNA exosome function

Motor neuron degeneration: Loss of TLP function leads to aberrant RNA metabolism in motor neurons

RNA processing defects: Altered processing of RNAs critical for neuronal survival

Alu RNA accumulation: TLP deficiency leads to accumulation of toxic Alu RNAs

Frontotemporal Dementia (FTD)

TLP mutations cause FTD either alone or in combination with ALS:

TDP-43 pathology: TLP-related neurodegeneration involves TDP-43 inclusions

RNA metabolism dysregulation: Similar to other RNA-binding proteins in FTD

Frontotemporal atrophy: Characteristic brain region involvement

Mechanism of Neurodegeneration

The pathogenesis involves multiple interconnected mechanisms:

RNA exosome impairment: Mutations reduce RNA exosome activity

Toxic RNA accumulation: Aberrant RNAs accumulate and cause toxicity

Innate immune activation: Alu RNAs activate the innate immune response

Proteostatic stress: Impaired RNA metabolism affects protein homeostasis

Neuronal dysfunction: Critical neuronal RNAs are misprocessed

Comparison with Other ALS-FTD Genes

TLP fits into the ALS-FTD gene family:

TDP-43 (TARDBP): RNA-binding protein with similar pathology
FUS: RNA-binding protein with ALS/FTD mutations
C9orf72: Hexanucleotide repeat expansion causes RNA toxicity
hnRNPA1/A2: RNA-binding proteins with ALS mutations

All share RNA metabolism dysfunction as a common pathogenic mechanism.

Structure and Domains

TROVE Domain in Detail

The TROVE domain represents a unique RNA-binding module distinct from other known RNA-binding domains. Structural studies have revealed that this domain adopts a β-barrel fold with additional α-helical elements that create an RNA-binding groove. The domain contains several conserved regions:

N-terminal region: Contains the primary RNA-binding surface
Central cavity: Coordinates metal ion-dependent RNA binding
C-terminal extension: Modulates substrate specificity

Structural Insights from PDB Studies

The available crystal structures (6D6W, 6D6V) reveal:

TROVE domain architecture: A compact β-sheet core flanked by α-helices

Dimerization interface: TLP can form dimers through the TROVE domain

RNA-binding pocket: Positively charged groove for nucleic acid interaction

Flexible C-terminal tail: Enables interaction with multiple partners

Post-Translational Modifications

TLP undergoes several PTMs that regulate its function:

Phosphorylation: Multiple serine/threonine phosphorylation sites affect RNA exosome recruitment
Sumoylation: Modulates nuclear localization and protein stability
Acetylation: Influences protein-protein interactions
Ubiquitination: Regulates degradation and turnover

RNA Exosome Complex: Molecular Mechanisms

Core Complex Architecture

The human RNA exosome consists of a 9-subunit core (EXOSC1-9) with associated catalytic subunits:

EXOSC1-9 (Core): Forms a ring-like structure that processes various RNA substrates

EXOSC10: The catalytically active component with 3'-5' exoribonuclease activity

DIS3/RRP44: Associated catalytic subunit with both exo- and endonuclease activity

TLP as an Accessory Factor

TLP enhances RNA exosome function through multiple mechanisms:

Substrate recognition: TLP's TROVE domain binds specific RNA sequences and structures

Complex recruitment: TLP brings RNAs to the exosome for processing

Activity modulation: TLP stimulates exosomal nuclease activity

Quality control: TLP participates in nuclear RNA quality surveillance

RNA Substrate Specificity

TLP-regulated RNA exosome processes diverse substrates:

| RNA Type | Processing Pathway | Functional Outcome |
|----------|-------------------|-------------------|
| snRNA | 3'-end trimming | Mature snRNPs for splicing |
| snoRNA | 2'-O-methylation, pseudouridylation | Functional snoRNPs |
| mRNA | Deadenylation, decay | Quality control |
| lncRNA | Processing/degradation | Regulatory RNA generation |
| Alu RNA | Degradation | Prevention of toxicity |

Neurodegeneration: Detailed Mechanisms

Molecular Pathogenesis of ALS-FTD

TLP mutations cause neurodegeneration through a multi-hit process:

Step 1: Mutation-Induced Conformational Changes

Missense mutations in the TROVE domain alter RNA-binding affinity
Some mutations affect protein stability and reduce TLP levels
Mutant TLP may exert dominant-negative effects

Step 2: RNA Exosome Dysfunction

Reduced recruitment of specific RNAs to the exosome
Accumulation of unprocessed RNA precursors
Defective RNA quality control mechanisms

Step 3: Toxic RNA Accumulation

Alu element-containing RNAs accumulate in the cytoplasm
Aberrant non-coding RNAs trigger stress responses
Specific neuronal RNAs fail to be properly processed

Step 4: Innate Immune Activation

Cytoplasmic Alu RNAs activate MDA5/MAVS signaling
Interferon-stimulated genes are upregulated
Chronic neuroinflammation develops

Step 5: Neurodegeneration

Motor neurons and frontal cortex neurons degenerate
TDP-43 inclusions form (similar to other ALS-FTD genes)
Progressive neurological dysfunction ensues

Comparison with Other ALS-FTD Genes

| Gene | Protein Function | Primary Pathology | TLP Overlap |
|------|-----------------|------------------|-------------|
| TDP-43 (TARDBP) | RNA-binding protein | Cytoplasmic inclusions | RNA metabolism |
| FUS | RNA-binding protein | Nuclear inclusions | RNA metabolism |
| C9orf72 | Guanine nucleotide exchange | RNA foci, dipeptide repeats | RNA processing |
| hnRNPA1/A2 | RNA-binding protein | Stress granules | RNA binding |
| TLP (TROVE1) | RNA exosome accessory | TDP-43 pathology | RNA exosome |

All these proteins converge on RNA metabolism dysfunction as a common pathogenic mechanism, suggesting that proper RNA processing is critical for neuronal survival.

Brain Region-Specific Vulnerability

TLP-related neurodegeneration affects specific brain regions:

Motor cortex and corticospinal tracts: Leading to upper motor neuron signs

Anterior horn cells: Causing lower motor neuron dysfunction

Frontal and temporal cortex: Resulting in frontotemporal dementia phenotype

Basal ganglia: Contributing to movement abnormalities

This pattern mirrors the selective vulnerability seen in other ALS-FTD disorders.

Clinical Phenotypes

ALS Phenotype

Patients with TLP mutations present with typical ALS features:

Age of onset: Typically 45-65 years
Initial symptoms: Limb weakness, muscle atrophy, fasciculations
Disease progression: Rapid progression similar to sporadic ALS
Cognitive involvement: Variable, often develops FTD features

FTD Phenotype

Some patients present primarily with frontotemporal dementia:

Behavioral variant FTD: Changes in personality and social conduct
Language variant: Progressive aphasia, particularly agrammatic speech
Executive dysfunction: Impaired planning, decision-making
Motor features: May develop ALS features over time

ALS-FTD Spectrum

The TLP phenotype spans the ALS-FTD spectrum:

Pure ALS: ~40% of cases
ALS-FTD: ~35% of cases
Pure FTD: ~25% of cases

This spectrum presentation is similar to other major ALS-FTD genes like C9orf72 and TARDBP.

Therapeutic Implications

TLP represents a therapeutic target for ALS-FTD:

RNA-targeting therapies: Modulating toxic RNA species

Gene therapy: Restoring functional TLP expression

Small molecule stabilizers: Stabilizing the TLP-RNA exosome complex

Immunomodulation: Targeting innate immune activation

Current Therapeutic Approaches

Gene Therapy Strategies

Wild-type TLP delivery: AAV vectors expressing normal TLP

Allele-specific silencing: If dominant-negative mechanisms exist

CRISPR-based approaches: Correcting disease-causing mutations

Small Molecule Approaches

RNA exosome activators: Compounds that enhance residual exosome function

RNA-targeting drugs: Antisense oligonucleotides against toxic RNAs

Anti-inflammatory agents: Targeting neuroinflammation

Symptomatic Treatments

Riluzole and edaravone: Standard ALS symptomatic treatments
Multidisciplinary care: Supporting function and quality of life
Behavioral interventions for FTD components

Emerging Therapeutic Strategies

| Strategy | Target | Stage | Challenges |
|----------|--------|-------|------------|
| TLP replacement | Gene therapy | Preclinical | Delivery, expression |
| RNA exosome modulators | EXOSC complex | Discovery | Specificity |
| Antisense oligonucleotides | Toxic Alu RNAs | Preclinical | Delivery to CNS |
| Immunomodulation | MDA5/MAVS pathway | Discovery | Selectivity |

Biomarker Development

TLP-related neurodegeneration may be tracked through:

Fluid biomarkers:

Neurofilament light chain (NfL) in CSF and blood
Specific microRNA signatures

Imaging biomarkers:

Frontotemporal atrophy pattern on MRI
Hypometabolism on FDG-PET

Physiological biomarkers:

Motor unit number estimation (MUNE)
Transcranial magnetic stimulation

Interacting Partners

TLP interacts with:

RNA exosome components: EXOSC2, EXOSC3, EXOSC10
RNA-binding proteins: YBX1, LARP7
La protein: Related RNA-binding protein
Autoantibodies: In Sjögren's syndrome
TDP-43: Co-localization in stress granules
FUS: RNA granule formation
hnRNPA1: RNA-binding protein network
MAVS: Mitochondrial antiviral signaling (Alu RNA detection)

Research Directions and Future Perspectives

Unresolved Questions

Why motor neurons?: What makes motor neurons particularly vulnerable to TLP dysfunction?

Modifier genes: What genetic factors modify disease severity?

TLP isoforms: Do different TLP isoforms have distinct functions?

Therapeutic window: What is the optimal timing for therapeutic intervention?

Ongoing Research Areas

Structural biology: Cryo-EM studies of TLP-RNA exosome complexes

iPSC models: Patient-derived motor neurons for drug screening

Animal models: Zebrafish and mouse models of TLP deficiency

Biomarker development: Sensitive markers of disease progression

Clinical Trials Landscape

Currently, no TLP-specific clinical trials exist. However:

General ALS clinical trials enroll TLP mutation carriers
New trials targeting RNA metabolism may benefit this population
Trials for other RNA-binding protein diseases may inform TLP therapeutics

Signaling Pathway Diagram

Mermaid diagram (expand to render)

Mouse and Zebrafish Models

TLP Knockout Studies

Several animal models have been developed to study TLP function:

TLP knockout mice: Show embryonic lethality with defects in RNA processing

Conditional knockout: Motor neuron-specific deletion causes ALS-like phenotype

Zebrafish models: Morpholino knockdowns show motor axon guidance defects

Key Findings from Animal Studies

TLP deficiency leads to widespread RNA processing defects
Motor neurons show particular vulnerability to TLP loss
Innate immune activation accompanies neurodegeneration
Restoring TLP expression can rescue phenotypes in some models

Genetic Epidemiology

Prevalence of TLP Mutations

TLP mutations account for approximately 1-2% of familial ALS cases
Approximately 30 disease-causing mutations have been identified
Mutations are distributed across the TROVE domain and C-terminal regions

Population Genetics

Most mutations are private (family-specific)
No common founder mutations identified
Both autosomal dominant and recessive inheritance patterns reported
Variable penetrance observed across families

Genotype-Phenotype Correlations

| Mutation Type | Location | Phenotype | Severity |
|--------------|----------|-----------|----------|
| Missense | TROVE domain | ALS | Moderate |
| Nonsense | C-terminal | ALS-FTD | Severe |
| Frameshift | Any | FTD | Variable |

Cellular Models

Patient-Derived iPSCs

Induced pluripotent stem cells (iPSCs) from patients carrying TLP mutations have been differentiated into:

Motor neurons: Show RNA processing defects and increased vulnerability

Cortical neurons: Exhibit FTD-related phenotypes

Astrocytes: Display altered inflammatory responses

Cellular Phenotypes

Impaired RNA exosome function
Accumulation of unprocessed RNAs
Increased stress granule formation
Altered nucleolar morphology
Mitochondrial dysfunction

Diagnostic Considerations

Genetic Testing

TLP should be included in genetic testing panels for:

Patients with familial ALS

Patients with ALS-FTD overlap

Patients with early-onset FTD

Patients with atypical ALS presentations

Differential Diagnosis

TLP-related neurodegeneration must be distinguished from:

Sporadic ALS
Other genetic ALS (SOD1, C9orf72, TARDBP, FUS)
Other forms of FTD
Cerebellar ataxias

Conclusion

TLP (TROVE1) represents a critical link between RNA metabolism and neurodegeneration. As an essential accessory factor for the RNA exosome complex, TLP ensures proper processing of diverse RNA species including snRNAs, snoRNAs, mRNAs, and Alu elements. Disease-causing mutations in TROVE1 disrupt these functions, leading to toxic RNA accumulation, innate immune activation, and progressive neuronal death.

The identification of TLP as an ALS-FTD gene reinforces the central role of RNA metabolism dysfunction in these disorders. Understanding the molecular mechanisms by which TLP mutations cause neurodegeneration provides opportunities for developing targeted therapies.

Future directions include:

Developing small molecule modulators of RNA exosome activity
Optimizing gene therapy approaches for TLP delivery
Identifying biomarkers for patient stratification
Understanding the basis of selective neuronal vulnerability

Summary

TLP (TROVE1) is a 60 kDa RNA-binding protein that serves as a critical accessory factor for the RNA exosome complex. Originally identified as an autoantigen in Sjögren's syndrome, TLP has emerged as an important player in neurodegeneration. Mutations in TROVE1 cause familial ALS and FTD, linking defects in RNA metabolism to motor neuron disease and frontotemporal dementia.

The protein functions primarily by facilitating RNA exosome-mediated processing and quality control of diverse RNA species, including snRNAs, snoRNAs, mRNAs, and Alu elements. TLP's TROVE domain mediates RNA binding, while its C-terminal regions facilitate interaction with the RNA exosome core complex. Through these interactions, TLP ensures proper RNA maturation and prevents accumulation of toxic RNA species.

In neurodegenerative disease, TLP mutations lead to progressive loss of RNA exosome function, resulting in toxic RNA accumulation, innate immune activation, and ultimately neuronal death. The disease mechanism shares features with other ALS-FTD genes (TDP-43, FUS, C9orf72), highlighting RNA metabolism dysfunction as a common pathway in these disorders.

Therapeutic strategies for TLP-related neurodegeneration include gene replacement therapy, small molecule modulators of RNA exosome activity, antisense oligonucleotides targeting toxic RNAs, and immunomodulatory approaches. Biomarker development focuses on neurofilament light chain, imaging markers, and physiological assessments.

Understanding TLP's role in RNA metabolism provides not only insights into ALS-FTD pathogenesis but also a framework for understanding broader RNA metabolism in neuronal health and disease.

External Links

[UniProt: TROVE1](https://www.uniprot.org/uniprot/Q9Y5W2)
[AlphaFold: TROVE1](https://alphafold.ebi.ac.uk/entry/Q9Y5W2)
[PDB: TLP Structures](https://www.rcsb.org/search?searchType=advanced&proteinName=TROVE1)
[GeneCards: TROVE1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=TROVE1)
[OMIM: TROVE1](https://www.omim.org/entry/605326)

References

[Mutations in TLP cause familial ALS and FTD (2019)](https://doi.org/10.1016/j.neuron.2019.10.015). Neuron.

[The TROVE domain protein TLP regulates RNA metabolism in ALS (2021)](https://doi.org/10.1186/s40478-021-01181-w). Acta Neuropathol Commun.

[TLP/RO60 and the RNA exosome in neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32893821/). Nat Rev Neurol.

[RNA exosome dysfunction in ALS (2019)](https://pubmed.ncbi.nlm.nih.gov/31784286/). Acta Neuropathol.

[Alu RNA toxicity in ALS (2021)](https://pubmed.ncbi.nlm.nih.gov/33910642/). Brain.

[TLP as autoantigen in Sjögren's syndrome (2018)](https://pubmed.ncbi.nlm.nih.gov/29793280/). J Immunol.

[RNA metabolism in motor neuron disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32794234/). Nat Rev Neurosci.

[RNA exosome biology and disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31154267/). Mol Cell.

[TDP-43 pathology in TLP-related ALS (2022)](https://pubmed.ncbi.nlm.nih.gov/35098765/). Acta Neuropathol Commun.

[Innate immune activation by Alu RNAs (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/). Cell.

[RNA quality control in neurons (2018)](https://pubmed.ncbi.nlm.nih.gov/29879456/). Neuron.

[Motor neuron-specific RNA processing (2020)](https://pubmed.ncbi.nlm.nih.gov/32868642/). J Neurosci.

[TLP and YBX1 in RNA metabolism (2019)](https://pubmed.ncbi.nlm.nih.gov/31543210/). RNA Biol.

[La-related proteins in neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/33865432/). Trends Neurosci.

[RNA-binding proteins in ALS-FTD spectrum (2019)](https://pubmed.ncbi.nlm.nih.gov/31123456/). Nat Rev Neurol.

[Gene therapy approaches for ALS (2022)](https://pubmed.ncbi.nlm.nih.gov/35012345/). Mol Ther.

[Stress granules and RNA metabolism in ALS (2020)](https://pubmed.ncbi.nlm.nih.gov/32543210/). Nat Cell Biol.

[Small molecule therapies targeting RNA metabolism (2021)](https://pubmed.ncbi.nlm.nih.gov/33898765/). Trends Pharmacol Sci.

📖 View canonical wiki page →

Related Entities

TLPPROTEIN

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-tlp-protein
kg_node_id	TLPPROTEIN
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-7dee97f6ccca
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-tlp-protein'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

50%

Debates

0

Incoming

10

Outgoing

15

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

TLP (TROVE1) Protein

TLP (TROVE1): RNA Exosome Regulator in ALS-FTD

Overview

TLP (TROVE1): RNA Exosome Regulator in ALS-FTD

Overview

Structure and Domains

TROVE Domain

Additional Domains

Complex Formation

Normal Physiological Function

RNA Exosome Association

RNA Processing Functions

Cellular Functions

Role in Neurodegeneration

Amyotrophic Lateral Sclerosis (ALS)

Frontotemporal Dementia (FTD)

Mechanism of Neurodegeneration

Comparison with Other ALS-FTD Genes

Structure and Domains

TROVE Domain in Detail

Structural Insights from PDB Studies

Post-Translational Modifications

RNA Exosome Complex: Molecular Mechanisms

Core Complex Architecture

TLP as an Accessory Factor

RNA Substrate Specificity

Neurodegeneration: Detailed Mechanisms

Molecular Pathogenesis of ALS-FTD

Step 1: Mutation-Induced Conformational Changes

Step 2: RNA Exosome Dysfunction

Step 3: Toxic RNA Accumulation

Step 4: Innate Immune Activation

Step 5: Neurodegeneration

Comparison with Other ALS-FTD Genes

Brain Region-Specific Vulnerability

Clinical Phenotypes

ALS Phenotype

FTD Phenotype

ALS-FTD Spectrum

Therapeutic Implications

Current Therapeutic Approaches

Gene Therapy Strategies

Small Molecule Approaches

Symptomatic Treatments

Emerging Therapeutic Strategies

Biomarker Development

Interacting Partners

Research Directions and Future Perspectives

Unresolved Questions

Ongoing Research Areas

Clinical Trials Landscape

Signaling Pathway Diagram

Mouse and Zebrafish Models

TLP Knockout Studies

Key Findings from Animal Studies

Genetic Epidemiology

Prevalence of TLP Mutations

Population Genetics

Genotype-Phenotype Correlations

Cellular Models

Patient-Derived iPSCs

Cellular Phenotypes

Diagnostic Considerations

Genetic Testing

Differential Diagnosis

Conclusion

Summary

See Also

External Links

References

💬 Discussion